Could postinterferon treatment α‐fetoprotein levels truly predict hepatocarcinogenesis?
Gin‐Ho Lo – 12 February 2014
Gin‐Ho Lo – 12 February 2014
Julien Vergniol, Jérôme Boursier, Clélia Coutzac, Sandrine Bertrais, Juliette Foucher, Camille Angel, Faiza Chermak, Isabelle Fouchard Hubert, Wassil Merrouche, Frédéric Oberti, Victor Lédinghen, Paul Calès – 12 February 2014 – No data are available about the prediction of long‐term survival using repeated noninvasive tests of liver fibrosis in chronic hepatitis C (CHC). We aimed to assess the prognostic value of 3‐year liver stiffness measurement (LSM), aspartate aminotransferase to platelet ratio index (APRI), and fibrosis 4 (FIB‐4) evolution in CHC.
Ozlem Kucukoglu, Nurdan Guldiken, Yu Chen, Valentyn Usachov, Amin El‐Heliebi, Johannes Haybaeck, Helmut Denk, Christian Trautwein, Pavel Strnad – 12 February 2014 – Mallory‐Denk bodies (MDBs) are protein aggregates consisting of ubiquitinated keratins 8/18 (K8/K18). MDBs are characteristic of alcoholic and nonalcoholic steatohepatitis (NASH) and discriminate between the relatively benign simple steatosis and the more aggressive NASH.
Mickaël Lesurtel, Pierre‐Alain Clavien – 12 February 2014
Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja‐Wyszomirska, Gideon M. Hirschfield, Olivier Barbier, Piotr Milkiewicz – 12 February 2014 – Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10‐15 mg/kg/day) were included.
Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja‐Wyszomirska, Gideon M. Hirschfield, Olivier Barbier, Piotr Milkiewicz – 12 February 2014 – Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10‐15 mg/kg/day) were included.
Giorgina Mieli‐Vergani, Diego Vergani – 10 February 2014 – Watch a video presentation of this article
Michael R. Lucey, John M. Vierling – 10 February 2014 – Watch a video presentation of this article
Meredith Borman, Mark G. Swain – 10 February 2014 – Watch a video presentation of this article
Michael Ronan Lucey – 10 February 2014 – Watch a video presentation of this article